Endometrial Cancer Market Overview:
The
global endometrial cancer
market size is USD 24.08 Billion expecting a robust CAGR 4.2% and a
strong market presence during the forecast period 2023-2032 in an all-inclusive
study asserts Market Research Future (MRFR). Endometrial cancer is also known
as uterine cancer and is the sixth most common cancer in women across the
world. The daunting number speaks for itself and promotes the factors that
ensure the market growth for endometrial cancer.
Market Dashboard:
The
market is witnessing significant funding going into research and developments.
For instance, Salk Institutes is getting a sizeable amount of fund from Padres
Pedal the Cause. Others are mainly focusing on mergers and acquisitions. Royal
Philips acquiring EPD Solutions can be taken exemplary. Boston Scientific has
also acquired EMcision, Ltd.
The
prominent players involved in the market are
Pfizer
Inc.,
General
Electric Company,
Koninklijke
Philips N.V.,
LUPIN,
PHYTON,
Bayer
AG,
Celgene
Corporation,
Johnson
& Johnson,
CooperSurgical
Inc.,
LiNA
Medical USA,
Conceptus
Inc.,
Hologic
Inc.,
Karl
Storz GmbH & Co. Kg, and
Boston
Scientific Corporation.
Drivers and Restraints:
Urbanization
across the world is experiencing an express speed growth rate owing to which
the population is undergoing remarkable lifestyle change. A sedentary lifestyle
has become the norm for many, and growing obesity among women is resulting in
the rising number of endometrial cancer. Lack of nutritional elements in
consumed food and other diseases such as polycystic ovarian syndrome (PCOS) and
the ovarian tumor can trigger endometrial cancer.
However,
a few factors are currently acting as market irritants such as high diagnostic
cost, expensive treatment, and side-effects associated with the procedure.
Coupled with these factors, stringent government policies regarding the
treatment can also create a bottleneck situation for the market.
Industry Trends:
According
to the Journal of Clinical Oncology, researchers of John Hopkins Medicine have
found a new way to treat uterine cancer by adding the drug trastuzumab to the
chemotherapy regimen of the uterine cancer patients. The drug prolongs the
tumor growth process and gives the physicians a better opportunity to cure the
patients.
A
new finding by the researchers in Huntsman Cancer Institute (HCI) at the
University of Utah reveals that in many uterine cancer tissues steroid and
hormone receptors are acting simultaneously causing an escalation in the growth
of the tumor.
PapSEEK
is a type of liquid biopsy which is now enabling researchers to identify
endometrial cancer at a very early stage. The screening procedure is still in
its early stage, but it can surely benefit the doctors in diagnosing and
treating their patients.
Segmentation:
The
global endometrial cancer
market can be segmented by diagnosis, treatment, and end-user.
By
diagnosis, the market can further be segmented into the pelvic examination,
transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C),
and laparoscopy. Endometrial biopsy is very common as the confirmatory test for
uterine cancer.
Treatment-based
market includes hysterectomy techniques, radiation, hormone therapy,
chemotherapy, and palliative care. The hysterectomy techniques category
comprises open abdominal hysterectomy, total vaginal hysterectomy, total
laparoscopic hysterectomy, and robotic hysterectomy. External radiation and
internal radiation (brachytherapy) are part of radiation technology. The
hormonal therapy consists progestins, tamoxifen, luteinizing hormone-releasing
hormone agonists, and aromatase inhibitors. Chemotherapy can be further
sub-segmented into paclitaxel, carboplatin, doxorubicin, and cisplatin and is
also the most-used treatment method.
Based
on the end-users the market can be segmented into hospitals and clinics,
ambulatory surgical centers, diagnostic centers, gynecology centers, feminist
health centers, and others.
Regional Analysis:
Region-wise
the global endometrial cancer market covers the Americas, Europe, Asia-Pacific
(APAC), and the Middle East and Africa (MEA).
The
Americas are currently holding the largest market share and can continue to do
so in the near future. The region is experiencing a growing number of
endometrial patients who are spending much on diagnostic and treatment. The
region has a well-structured healthcare system and extensive research units who
are also contributing significantly to the regional market.
Europe
is currently holding the second position in the market. Robust healthcare
sector and advanced technologies are supporting the European market for uterine
cancer treatment.
The
APAC can also witness significant growth in the market owing to rising
incidence of cervical cancer in countries such as India and China.
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street,5Th Floor, New York,
New
York 10013
United
States of America
